A recent systematic review and meta-analysis suggests that the overall incidence of pneumonitis during PD-1 inhibitor monotherapy was 2.7% (95%CI, 1.9–3.6%) for all-grade and 0.8% (95%CI, 0.4–1.2%) for grade 3 or higher pneumonitis. This evidence concerns the gene PDCD1 and pneumonitis.